|Ms. Y. Y. Tse||Executive Chairwoman of the Board||38.75M||N/A||1992|
|Mr. Eric S. Y. Tse||CEO & Executive Director||25.47M||N/A||1996|
|Mr. Ping Tse||Founder & Senior Executive Vice Chairman||46.24M||N/A||1952|
|Ms. Cheung Ling Cheng||Executive Vice Chairwoman of the Board||32.61M||N/A||1964|
|Ms. Mingqin Li||Senior VP & Executive Director||1.32M||N/A||1959|
|Mr. Zhoushan Tian||Executive Director||2M||N/A||1964|
|Mr. Hsin Tse||Senior VP & Executive Director||6.43M||N/A||1970|
|Ms. Chun Ling Li||Chief Financial Officer||N/A||N/A||1972|
|Sean Chen||Chief Strategy Officer||N/A||N/A||N/A|
|Orphanides George||Chief Scientific Advisor of invoX||N/A||N/A||N/A|
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection. It also provides surgery/analgesia medicines comprising Debaian cataplasms and Gaisanchun soft capsules; and cardio-cerebral vascular medicines, including Yilunping and Kaina tablets. In addition, the company is involved in the long term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Sino Biopharmaceutical Limited’s ISS governance QualityScore as of 1 December 2023 is 7. The pillar scores are Audit: 4; Board: 2; Shareholder rights: 7; Compensation: 9.